Gut Microbiota–Platelet Axis and Thrombosis in Advanced Chronic Liver Disease

Abstract

Advanced chronic liver disease is characterized by metabolic-associated liver disease, metabolic-associated steatohepatitis, and cirrhosis. This clinical setting is associated with platelet activation, which has been suggested to play a role in the progression of liver disease; thus, platelet activation has been detected in portal circulation as well within liver sinusoids. Experimental studies with antiplatelet drugs and observational studies in human suggested a role for platelet activation in the mechanism of the disease. Furthermore, advanced chronic liver disease may be complicated by atherosclerotic complications, where the role of platelet activation is well consolidated. Platelet activation may represent a unique mechanism leading to liver disease on one hand and to atherosclerotic complications on the other hand. Several studies pointed to the role of gut dysbiosis as key step for eliciting platelet activation via the production of pro-aggregating metabolites such as trimethylamine N-oxide or translocation of bacterial products such as lipopolysaccharide into the systemic circulation. The aims of this narrative review are to show the experimental and clinical evidence relating platelets with advanced chronic liver disease, to explore the role of gut microbiota as mechanism for platelet activation, and to suggest novel therapeutic strategies to inhibit gut microbiota–platelet axis.

Keywords

blood platelets - dysbiosis - lipopolysaccharide - liver cirrhosis - liver diseases

Publication History

Received: 11 March 2025

Accepted: 04 June 2025

Accepted Manuscript online:
05 June 2025

Article published online:
14 July 2025

• References

• 1 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
• 2 Cammisotto V, Valeriani E, Pignatelli P, Violi F. Nicotinamide adenine dinucleotide phosphate oxidases and metabolic dysfunction-associated steatotic liver disease. Antioxidants 2025; 14 (01) 83
• 3 Roca-Fernandez A, Banerjee R, Thomaides-Brears H. et al. Liver disease is a significant risk factor for cardiovascular outcomes—a UK Biobank study. J Hepatol 2023; 79 (05) 1085-1095
• 4 Duell PB, Welty FK, Miller M. et al; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022; 42 (06) e168-e185
• 5 Violi F, Cammisotto V, Bartimoccia S. et al. Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. Nat Rev Cardiol 2023; 20 (01) 24-37
• 6 Violi F, Lip GY, Cangemi R. Endotoxemia as a trigger of thrombosis in cirrhosis. Haematologica 2016; 101 (04) e162-e163
• 7 Raparelli V, Basili S, Carnevale R. et al. Low-grade endotoxemia and platelet activation in cirrhosis. Hepatology 2017; 65 (02) 571-581
• 8 Violi F, Pignatelli P, Castellani V, Carnevale R, Cammisotto V. Gut dysbiosis, endotoxemia and clotting activation: a dangerous trio for portal vein thrombosis in cirrhosis. Blood Rev 2023; 57: 100998
• 9 Nishimura N, Kaji K, Kitagawa K. et al. Intestinal permeability is a mechanical rheostat in the pathogenesis of liver cirrhosis. Int J Mol Sci 2021; 22 (13) 6921
• 10 Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48 (02) 206-211
• 11 Ji Y, Yin Y, Sun L, Zhang W. The molecular and mechanistic insights based on gut-liver axis: nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement. Int J Mol Sci 2020; 21 (09) 3066
• 12 Buckley A, Turner JR. Cell biology of tight junction barrier regulation and mucosal disease. Cold Spring Harb Perspect Biol 2018; 10 (01) a029314
• 13 Johansson ME, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 2013; 10 (06) 352-361
• 14 Miele L, Valenza V, La Torre G. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49 (06) 1877-1887
• 15 Violi F, Pastori D, Pignatelli P, Cammisotto V. Endotoxemia and platelets: 2 players of intrahepatic microthrombosis in NAFLD. JACC Basic Transl Sci 2023; 9 (03) 404-413
• 16 Violi F, Nocella C, Bartimoccia S. et al. Gut dysbiosis-derived low-grade endotoxemia: a common basis for liver and cardiovascular disease. Kardiol Pol 2023; 81 (06) 563-571
• 17 Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?. J Hepatol 2011; 55 (06) 1415-1427
• 18 McConnell JP, Cheryk LA, Durocher A. et al. Urinary 11-dehydro-thromboxane B(2) and coagulation activation markers measured within 24 h of human acute ischemic stroke. Neurosci Lett 2001; 313 (1-2): 88-92
• 19 Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002; 13 (5-6): 301-306
• 20 Celikbilek M, Gürsoy S, Deniz K, Karaman A, Zararsiz G, Yurci A. Mean platelet volume in biopsy-proven non-alcoholic fatty liver disease. Platelets 2013; 24 (03) 194-199
• 21 Saremi Z, Rastgoo M, Mohammadifard M, Bijari B, Akbari E. Comparison of platelet number and function between nonalcoholic fatty liver disease and normal individuals. J Res Med Sci 2017; 22: 75
• 22 Violi F, Pignatelli P, Cammisotto V. Platelet defects in cirrhosis: fact or fiction. J Hepatol 2023; 79 (05) e197-e198
• 23 Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984; 59 (02) 123-125
• 24 Laffi G, Cominelli F, Ruggiero M. et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988; 8 (06) 1620-1626
• 25 Lecchi A, Tosetti G, Ghali C. et al. Comprehensive investigation of platelet function in patients with cirrhosis. Thromb Res 2024; 237: 64-70
• 26 Basili S, Raparelli V, Riggio O. et al; CALC Group. NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. Liver Int 2011; 31 (10) 1533-1540
• 27 Zanetto A, Toffanin S, Campello E. et al. Reticulated platelets are increased and hyper-activated in patients with cirrhosis, especially those with poor outcome. Dig Liver Dis 2024; 56 (08) 1327-1334
• 28 Pignatelli P, Carnevale R, Di Santo S. et al. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 2011; 31 (02) 423-434
• 29 Davì G, Ferro D, Basili S. et al. Increased thromboxane metabolites excretion in liver cirrhosis. Thromb Haemost 1998; 79 (04) 747-751
• 30 Zanetto A, Campello E, Bulato C. et al. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. J Hepatol 2022; 77 (03) 660-669
• 31 Scavone M, Podda GM, Tripodi A, Cattaneo M. Whole blood platelet aggregation measurement by Multiplate™: potential diagnostic inaccuracy of correcting the results for the sample platelet count. Platelets 2023; 34 (01) 2156493
• 32 Cheng X, Qiu X, Liu Y, Yuan C, Yang X. Trimethylamine N-oxide promotes tissue factor expression and activity in vascular endothelial cells: a new link between trimethylamine N-oxide and atherosclerotic thrombosis. Thromb Res 2019; 177: 110-116
• 33 Chen YM, Liu Y, Zhou RF. et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep 2016; 6: 19076
• 34 León-Mimila P, Villamil-Ramírez H, Li XS. et al. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metab 2021; 47 (02) 101183
• 35 Theofilis P, Vordoni A, Kalaitzidis RG. Trimethylamine N-oxide levels in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolites 2022; 12 (12) 1243
• 36 Loffredo L, Zicari AM, Perri L. et al. Does Nox2 overactivate in children with nonalcoholic fatty liver disease?. Antioxid Redox Signal 2019; 30 (10) 1325-1330
• 37 Violi F, Ferro D. Clotting activation and hyperfibrinolysis in cirrhosis: implication for bleeding and thrombosis. Semin Thromb Hemost 2013; 39 (04) 426-433
• 38 Nocella C, Carnevale R, Bartimoccia S. et al. Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. Thromb Haemost 2017; 117 (08) 1558-1570
• 39 Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, Poelstra K. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002; 18 (06) 561-566
• 40 Han YH, Onufer EJ, Huang LH. et al. Enterically derived high-density lipoprotein restrains liver injury through the portal vein. Science 2021; 373 (6553) eabe6729
• 41 Guerville M, Boudry G. Gastrointestinal and hepatic mechanisms limiting entry and dissemination of lipopolysaccharide into the systemic circulation. Am J Physiol Gastrointest Liver Physiol 2016; 311 (01) G1-G15
• 42 Carpino G, Del Ben M, Pastori D. et al. Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology 2020; 72 (02) 470-485
• 43 Queck A, Carnevale R, Uschner FE. et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut 2020; 69 (08) 1535-1536
• 44 Violi F, Ferro D, Basili S. et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995; 109 (02) 531-539
• 45 Ferro D, Quintarelli C, Lattuada A. et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23 (06) 1377-1383
• 46 Shalaby S, Simioni P, Campello E. et al. Endothelial damage of the portal vein is associated with heparin-like effect in advanced stages of cirrhosis. Thromb Haemost 2020; 120 (08) 1173-1181
• 47 Violi F, Carnevale R, Pignatelli P. “The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study”: comment from Violi et al. J Thromb Haemost 2023; 21 (01) 186-187
• 48 Driever EG, Magaz M, Adelmeijer J. et al. The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study. J Thromb Haemost 2022; 20 (09) 2075-2082
• 49 Miele L, Alberelli MA, Martini M. et al. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Transl Res 2021; 231: 24-38
• 50 Malehmir M, Pfister D, Gallage S. et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 2019; 25 (04) 641-655
• 51 FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67 (06) 1174-1177
• 52 An L, Wirth U, Koch D. et al. The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases. J Gastrointest Surg 2022; 26 (03) 671-683
• 53 Jian J, Nie MT, Xiang B. et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids. Front Pharmacol 2022; 13: 841132
• 54 Ramadori P, Klag T, Malek NP, Heikenwalder M. Platelets in chronic liver disease, from bench to bedside. JHEP Rep Innov Hepatol 2019; 1 (06) 448-459
• 55 Basili S, Raparelli V, Napoleone L. et al; PRO-LIVER Collaborators. Platelet count does not predict bleeding in cirrhotic patients: results from the PRO-LIVER study. Am J Gastroenterol 2018; 113 (03) 368-375
• 56 Hofer BS, Brusilovskaya K, Simbrunner B. et al. Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis. Hepatology 2024; 80 (05) 1120-1133
• 57 Campello E, Zanetto A, Radu CM. et al. Profiling plasma alterations of extracellular vesicles in patients with acutely decompensated cirrhosis and bacterial infection. Liver Int 2024; 44 (07) 1610-1623
• 58 Shalaby S, Zanetto A, Campello E. et al. Reply to “Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis”. Platelets 2022; 33 (07) 1104-1106
• 59 Perrella G, Nagy M, Watson SP, Heemskerk JWM. Platelet GPVI (glycoprotein VI) and thrombotic complications in the venous system. Arterioscler Thromb Vasc Biol 2021; 41 (11) 2681-2692
• 60 Zanetto A, Campello E, Burra P, Senzolo M, Simioni P. Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis. Liver Int 2023; 43 (01) 155-159
• 61 Pavord S, Scully M, Hunt BJ. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385 (18) 1680-1689
• 62 Afdhal NH, Giannini EG, Tayyab G. et al; ELEVATE Study Group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367 (08) 716-724
• 63 Cangemi R, Raparelli V, Talerico G, Basili S, Violi F. PRO-LIVER Collaborators. Hypoalbuminemia and risk of portal vein thrombosis in cirrhosis. Gastro Hep Adv 2024; 3 (05) 646-653
• 64 Basili S, Carnevale R, Nocella C. et al; PRO-LIVER Collaborators. Serum albumin is inversely associated with portal vein thrombosis in cirrhosis. Hepatol Commun 2019; 3 (04) 504-512
• 65 Violi F, Ceccarelli G, Loffredo L. et al. Albumin supplementation dampens hypercoagulability in COVID-19: a preliminary report. Thromb Haemost 2021; 121 (01) 102-105
• 66 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020; 69 (09) 1691-1705
• 67 Baratta F, Pastori D, Angelico F. et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol 2020; 18 (10) 2324-2331.e4
• 68 Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65 (03) 589-600
• 69 Baigent C, Blackwell L, Collins R. et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678) 1849-1860
• 70 Fujita K, Nozaki Y, Wada K. et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008; 57 (11) 1583-1591
• 71 Shen H, Shahzad G, Jawairia M, Bostick RM, Mustacchia P. Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2014; 40 (09) 1066-1073
• 72 Simon TG, Henson J, Osganian S. et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019; 17 (13) 2776-2784.e4
• 73 Thongtan T, Deb A, Vutthikraivit W. et al. Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Indian J Gastroenterol 2022; 41 (02) 119-126
• 74 Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021; 75 (Suppl. 01) S67-S81
• 75 Ghosh S, Whitley CS, Haribabu B, Jala VR. Regulation of intestinal barrier function by microbial metabolites. Cell Mol Gastroenterol Hepatol 2021; 11 (05) 1463-1482
• 76 Fukui H. Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia. World J Hepatol 2015; 7 (03) 425-442
• 77 Cani PD, Possemiers S, Van de Wiele T. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58 (08) 1091-1103
• 78 Ghosh SS, Wang J, Yannie PJ. et al. Over-expression of intestinal alkaline phosphatase attenuates atherosclerosis. Circ Res 2021; 128 (11) 1646-1659
• 79 Simon TG, Wilechansky RM, Stoyanova S. et al. Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial. JAMA 2024; 331 (11) 920-929